Ovid Therapeutics (OVID) Revenue & Revenue Breakdown
Ovid Therapeutics Revenue Highlights
Latest Revenue (Y)
$7.25M
Main Segment (Y)
Reportable Segment
Ovid Therapeutics Revenue by Period
Ovid Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $7.25M | 1181.27% |
| 2024-12-31 | $566.00K | 44.39% |
| 2023-12-31 | $392.00K | -73.91% |
| 2022-12-31 | $1.50M | -99.28% |
| 2021-12-31 | $208.38M | 1551.57% |
| 2020-12-31 | $12.62M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | - |
Ovid Therapeutics generated $7.25M in revenue during NA 2025, up 1181.27% compared to the previous quarter, and up 57.48% compared to the same period a year ago.
Ovid Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-09-30 | - | -100.00% |
| 2026-06-30 | $733.00K | 100.00% |
| 2026-03-31 | - | -100.00% |
| 2025-12-31 | $718.00K | 443.94% |
| 2025-09-30 | $132.00K | -97.90% |
| 2025-06-30 | $6.27M | 4724.62% |
| 2025-03-31 | $130.00K | 71.05% |
| 2024-12-31 | $76.00K | -56.07% |
| 2024-09-30 | $173.00K | 2.37% |
| 2024-06-30 | $169.00K | 14.19% |
| 2024-03-31 | $148.00K | 4.23% |
| 2023-12-31 | $142.00K | 30.28% |
| 2023-09-30 | $109.00K | 45.33% |
| 2023-06-30 | $75.00K | 13.64% |
| 2023-03-31 | $66.00K | 42.61% |
| 2022-12-31 | $46.28K | 316.86% |
| 2022-09-30 | $11.10K | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $1.45M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2021-03-31 | $208.38M | 3553.80% |
| 2020-12-31 | $5.70M | -17.51% |
| 2020-09-30 | $6.91M | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | - |
Ovid Therapeutics generated - in revenue during Q3 2026, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Ovid Therapeutics Revenue Breakdown
Ovid Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 22 | Dec 21 |
|---|---|---|---|
| Reportable Segment | $7.25M | - | - |
| License | - | $1.50M | $12.38M |
| Related Party | - | - | $196.00M |
Latest
Ovid Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 22 | Sep 22 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $733.00K | $718.00K | $132.00K | $6.27M | $130.00K | - | - | - | - |
| License | - | - | - | - | - | $46.28K | $11.10K | $1.45M | $12.38M |
| Related Party | - | - | - | - | - | - | - | - | $196.00M |
Latest
Ovid Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Reportable Segment (100.00%).
Ovid Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 22 | Mar 22 | Mar 21 |
|---|---|---|---|
| Related Party | - | - | $196.00M |
| License | $11.10K | $1.45M | $12.38M |
Latest
Ovid Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 22: License (100.00%).
Ovid Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical | $673.00M | $173.00M |
| STOK | Stoke Therapeutics | $184.42M | $11.26M |
| WVE | Wave Life Sciences | $42.73M | $13.16M |
| VYGR | Voyager Therapeutics | $40.37M | $4.01M |
| MGTX | MeiraGTx | $33.28M | $4.81M |
| TSHA | Taysha Gene Therapies | $9.77M | - |
| OVID | Ovid Therapeutics | $7.25M | - |
| ABEO | Abeona Therapeutics | $5.82M | $13.49M |
| NGNE | Neurogene | - | - |
| RCKT | Rocket Pharmaceuticals | - | - |
| LXEO | Lexeo Therapeutics | - | - |